GSK249320单克隆抗体治疗卒中患者的IIb期随机对照试验
这项IIb期双盲随机安慰剂对照试验在30个中心纳入134例缺血性卒中后24-72小时伴步态障碍患者,比较GSK249320与安慰剂对步速的影响。预设中期分析因达到无效性标准而终止,第90天步速变化两组无差异,药物耐受性好且未检出中和抗体。
要点
- GSK249320在卒中后72小时内给药未改善步速。
- 试验因预设无效性标准在中期分析时终止。
- 药物耐受性良好且未检出中和抗体。
核心结论
- GSK249320在卒中后72小时内给药,与安慰剂相比未改善步速。
研究设计与样本
- IIb期双盲随机安慰剂对照研究,30个中心,134例缺血性卒中后24-72小时伴步态障碍患者。
主要发现
- 第90天步速变化GSK249320组为0.55±0.46,安慰剂组为0.56±0.50。
- 包括上肢功能在内的次要终点结果一致。
- 两次静脉输注GSK249320耐受性良好,未检出中和抗体。
关键数值与推荐
- 主要结局为基线至第90天步速变化。
- 研究因预设中期分析达到无效性标准而终止。
局限性
- 研究提前终止,可能限制对结果的全面解读。
- 无直接证据表明治疗到达生物靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: One class of poststroke restorative therapy focuses on promoting axon outgrowth by blocking myelin-based inhibitory proteins such as myelin-associated glycoprotein. The purpose of the current study was to extend preclinical and clinical findings of GSK249320, a humanized monoclonal antibody to myelin-associated glycoprotein with disabled Fc region, to explore effects on motor outcomes poststroke. METHODS: In this phase IIb double-blind, randomized, placebo-controlled study, patients at 30 centers with ischemic stroke 24 to 72 hours prior and gait deficits were randomized to 2 IV infusions of GSK249320 or placebo. Primary outcome measure was change in gait velocity from baseline to day 90. RESULTS: A total of 134 subjects were randomized between May 2013 and July 2014. The 2 groups were overall well matched at baseline. The study was stopped at the prespecified interim analysis because the treatment difference met the predefined futility criteria cutoff; change in gait velocity to day 90 was 0.55±0.46 (mean±SD) in the GSK249320 group and 0.56±0.50 for placebo. Secondary end points including upper extremity function were concordant. The 2 IV infusions of GSK249320 were well tolerated. No neutralizing antibodies to GSK249320 were detected. CONCLUSIONS: GSK249320, within 72 hours of stroke, demonstrated no improvement on gait velocity compared with placebo. Possible reasons include challenges translating findings into humans and no direct evidence that the therapy reached the biological target. The antibody was well tolerated and showed low immunogenicity, findings potentially useful to future studies aiming to use a monoclonal antibody to modify activity in specific biological pathways to improve recovery from stroke. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01808261.
引用
- Cramer SC, Enney LA, Russell CK, et al. Proof-of-Concept Randomized Trial of the Monoclonal Antibody GSK249320 Versus Placebo in Stroke Patients. Stroke. 2017. PMID: 28228578. doi:10.1161/STROKEAHA.116.014517
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。